Next Phase Newsletter

The firm is a healthcare-focused venture investment fund. The core members are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The firm past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. These investments were over $10MM and were made in venture rounds from Series A-C. The firm currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas. The firm believes in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years.

The firm has invested in therapeutics in a wide range of indications, including cancer, infectious diseases and autoimmune disorders. These investments covered a wide range of modalities including small molecules, antibodies and gene therapies. The firm additionally invested in medical device and imaging technologies, such as ultrasound and cardiovascular devices. Therapeutic investments were made during pre-clinical trials, while device investments were made pre-market. The firm invested in bioinformatics, research tools and animal medicine as well. The firm has invested in companies in the US, China and Western Europe.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A large investment group with office in USA and Europe have invested in 265 companies across 55 countries. The firm is very active in the pharmaceutical and biotech industry, with around 70% of their portfolio being within these sectors. The firm has activity in listed companies, where they have interest in being a minority shareholder, with an investment size ranging from $10M to $200M. The firm is also interested in pre- IPO companies, with an investment size ranging from $5M to $200M in the form of equity, however the firm is only interested in companies that are planning on being listed in the stock exchange in the next 12 – 24 months. The firm has been successful in listing companies in the stock exchange, having done so with 4 companies so far, so their goal is to invest in companies who have that strategy. The firm is open to global opportunities.

The firm is looking for opportunities within the therapeutics, diagnostics and medical device sectors. The firm is agnostic in terms of subsector and indication, and will invest in all three classes of medical devices. The firm is open to pre-clinical companies.

The firm is open to all types of management teams with the caveat that the company must be planning on going public in the next 2 years. The firm prefers to lead investments and does not require a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital firm based in Western Europe with an additional office in USA closed its latest fund in 2019. The firm typically makes equity investment into early-stage life science companies. The typical investment size ranges from €5 million-€10 million. The third fund is looking to make 10 investments. The firm’s current fund is focused on the EU but the firm also invests in the US.

The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutics companies targeting drug delivery and gene therapy. The firm was also active in device companies developing single use cardiovascular devices and implantable devices.

The firm primarily invests in private companies with experienced management teams, but has the ability to also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused venture investment fund is backed by a core investment team with members all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The firm’s past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. These investments were over $10MM and were made in venture rounds from Series A-C. The firm currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas. The firm believes in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years.

The firm has invested in therapeutics in a wide range of indications, including cancer, infectious diseases and autoimmune disorders. These investments covered a wide range of modalities including small molecules, antibodies and gene therapies. The firm additionally invested in medical device and imaging technologies, such as ultrasound and cardiovascular devices. Therapeutic investments were made during pre-clinical trials, while device investments were made pre-market. The firm invested in bioinformatics, research tools and animal medicine as well. The firm has invested in companies in the US, China and Western Europe.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A clinical stage biopharmaceutical company headquartered in China with additional offices throughout USA and China is dedicated to antibody-based biotherapeutics discovery, research, development, and manufacturing. The firm is actively looking for early-stage opportunities to supplement their pipeline, and can engage in various types of partnerships including in-licensing, equity investment, and M&A. The firm is open to global opportunities.

The firm is primarily interested in early-stage, pre-clinical therapeutics companies, and will consider clinical opportunities up to Phase IIa. The firm’s modalities of interests extends beyond antibodies and the firm is also interested in identifying cutting-edge ADCs, biologics, cell therapies, etc. The firm focuses on the following indications: oncology, ophthalmology, nephrology, and bone disorders. The firm will generally not consider opportunities in medical devices, diagnostics, or digital health.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An established group of companies headquartered in Dubai, UAE specializes in the steel and oil industries is run by a family of doctors. Outside of their business in these industries, the firm actively makes direct investments into life science companies in Seed to Series A rounds, and sometimes Series B. Initial average check sizes are between $500k – 1M, though the firm has invested up to $2M. The group does occasionally participate in pre-IPO rounds with larger commitments, but this has been in companies outside of the life sciences industry. In addition, the group is an LP in some micro-VCs that invest in various sectors, and works with them to identify promising co-investment opportunities. The group has mainly considered opportunities in USA and Western Europe, but is open to all companies across the globe with the exception of India, as the group already has a strong network there.

Within life sciences, the firm is most interested in medical device companies and has looked into surgical devices, robotics, etc. The firm is open to all regulatory pathways, but prefers 510k companies. Current areas of interest include elderly care/longevity, genetics, and microbiome. The group will not consider therapeutics or in vitro diagnostics companies; digital health may be considered but is not a high priority.

The group has no specific company or management team requirements. The firm usually acts as a co-investor. The group has a strong hospital network in India as part of their business, and they actively help with the due diligence process.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A Boston-based life sciences accelerator founded in 2016 funds, supports and advances life science technologies from early development through clinical proof-of-concept. The accelerator’s experienced leadership team works with scientists and entrepreneurs to provide active mentorship, financing solutions and operational guidance to increase the probability of success in early drug development. The accelerator has access to capital to support companies from seed investment through Series A and B financings through the accelerator and a $210M venture fund. The size of initial seed investment can range from $0.5M to $1.5M. The subsequent Series A investments will be sized to get through preclinical and IND-enabling work and/or through a clinical development study and can range between $8M-$20M, with flexibility to syndicate with investors for larger rounds. For more mature companies that don’t require a seed round or the need to do complete activities/studies prior to a Series A, the venture fund can invest directly as a Series A investment along with participation in related Series B investments. Lastly, the venture fund is part of some later-stage funds, which can support companies in later-stage private/mezzanine/crossover financings, debt financings, and IPO/follow-on public offerings. The firm is open to global opportunities.

The accelerator and venture fund support opportunities across all therapeutic areas and drug modalities (small molecule, peptides, antibodies, genetic technologies, cell therapy, etc.). Additionally, open to technologies beyond drug therapeutics, including medical devices, diagnostics and emerging healthtech opportunities (digital health, telemedicine, enabling technologies utilizing AI/ML, etc.). Founder and entrepreneur friendly, supportive of first-time CEOs, and works side by side to drive value inflections with the goal to optimize program development and successful outcomes.

The accelerator is open to working with all types of management teams, including first time entrepreneurs. The group works hands-on with its portfolio companies by bringing a powerful network, access to resources and expertise to support their growth. The firm prefers to lead but is open to participating with likeminded co-investors to form syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.